News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Cost Body Endorses Celgene (CELG) Blood Cancer Drug


2/17/2011 6:45:56 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (Nasdaq:CELG) today announced that the National Institute for Health and Clinical Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending VIDAZA within its licensed indication, as an option for the treatment of patients in England and Wales with myelodysplastic syndromes (MDS) and acute myeloid leukaemia. NICE determined that VIDAZA, as an innovative, life-extending therapy, is a cost-effective use of National Health Service (NHS) resources.

Read at Reuters
Read at Pharma Times [Free Reg Req'd]
Read at News Release
Read at Telegraph
Read at BioSpace.com

comments powered by Disqus
Celgene
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES